One of the best recent technological advancements in the field of managing diabetes is glucose monitoring. A biosensor is incorporated with a CGM system, a specific kind of glucose monitoring device, via a transcutaneous or subcutaneous technique. The embedded gadget detects the glucose levels in interstitial fluid or blood. It sends the data via a transmitter to a receiver or monitor to show the results. Due to their significant advantages over conventional glucose monitoring techniques, these devices are crucial for managing diabetes. These gadgets provide routine glucose monitoring, which is necessary for avoiding diabetic complications in comparison to conventional glucose displays.

Business Research Insights estimates that the glucose monitoring market size was valued at USD 6827.1 million in 2021 and is expected to reach 10420 billion by 2028, exhibiting a CAGR of 6.2% during the forecast period.

Post COVID-19 Impact: Rising Production Activities and Increased Electric Vehicle Sales Propelled Industry Growth

The COVID-19 virus had a favorable effect on the development of the blood glucose monitoring device market. Due to the pandemic's emergence, many well-known players reported growth in their diabetes care earnings. Additionally, the COVID-19 pandemic has brought about new determination to assess the likelihood of CGM in hospitals in order to continuously monitor diabetic patients and to restrict healthcare professionals' access.

Target Population:

The safe use of CGMs will be ensured by proper patient selection. Patients should be technically proficient, motivated to participate in their diabetic treatment, and knowledgeable about diabetes. Compared to retrospective monitors, real-time monitors require these qualities even more. For calibration, currently accessible CGMs need up to four finger-stick blood glucose readings each day (instead of readings from an alternative site). Instead of shortly after exercise or when the blood glucose level is likely to be rising or falling, the best time to calibrate is either after fasting or at least 3 hours postprandially. Continuous readings could be inaccurate in the absence of such calibration. Because they are not reliable enough, currently available CGMs that offer real-time readings shouldn't be utilized to make treatment decisions like whether to dose insulin or eat.

Diabetes is a leading cause of blindness, kidney failure, heart attacks, strokes, and lower limb amputations, according to the World Health Organization (WHO). The WHO also notes that low- and middle-income countries are experiencing a faster rise in diabetes incidence.

The prevalence of diabetes and obesity is posing a serious threat to the global healthcare system, and the need for appropriate diabetes treatment is growing as the number of elderly people worldwide, who are predisposed to diabetes, rises.

Biosensors for Monitoring Glucose:

Three components make up a biosensor: a bioreceptor, which serves as the recognition component, a signal transducer, and a signal displayer, which is typically an electronic system (Liu et al., 2019). A biological analyte, such as a molecule or structure, is detected by the device through binding, and it then transmits the analyte's concentration in the sample solution. The two basic kinds of biosensors are affinity biosensors, which rely on DNA and antibodies, and catalytic biosensors, which are based on enzyme reactions. There are other classes of biosensors with various binding types and outputs (Shukla et al., 2016). The enzyme glucose oxidase (GOD) is frequently used in CGMs as the recognition molecule to bond with glucose. Although enzyme glucose biosensors are precise and sensitive, this approach has several limitations.

For instance, it is unstable and easily influenced by variations in temperature, pH, and humidity. To combat these instabilities, several efforts have been made to explore enzymatic biosensors, for as by employing an artificial nanozyme (Vokhmyanina et al., 2020). Non-enzymatic biosensors exhibit encouraging benefits since they are unaffected by conditions that confound enzyme biosensors (Lee et al., 2016). A recognition molecule for the detection of glucose can also be an aptamer.

Future Growth Scenario of the Industry

The development of closed-loop solutions in particular has drawn a lot of interest recently since they offer the potential to fully automate the diabetes treatment process, improving patient outcomes. As a result, the successful introduction of such a device may be able to expand the already heavily saturated market for insulin infusion pumps. Over the past few years, there has been a proliferation of businesses among manufacturers of insulin pumps, including Tandem Diabetes Care and Insulet, alongside CGM industry giants Abbott and Dexcom for the expansion of hybrid closed-loop systems.